Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Variants & evidence
259 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PTEN Expression1 | ||||||||
| Erlotinib + GefitinibSubstitutes | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1129Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment w… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC | civic |
| PTEN Mutation3 | ||||||||
| (diagnostic) | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports Positive | 2 | accepted | EID1931Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compar… (full text at CIViC) PMID 9331072 · Rasheed et al., 1997 · Open in CIViC | civic |
| Buparlisib | GlioblastomaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7074In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC) PMID 30715997 · Wen et al., 2019 · Open in CIViC | civic |
| Nivolumab + PembrolizumabSubstitutes | Glioblastoma | |||||||
| PTEN R173C2 | ||||||||
| (diagnostic) | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports N/A | 3 | rejected | EID1932Bostrom et al identified R173C in the tumor sample of 1 subject (out of 36 glioblastomas tested). By PCR mRNA expression of PTEN was assayed for tumor samples harboring PTEN variants. PTEN expression… (full text at CIViC) PMID 9426052 · Boström et al., 1998 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports N/A | 2 | submitted | EID1933Fults et al identified 1 R173C mutation in a glioblastoma (of 45 tested). The tumor also displayed either all or partial LOH of 10q, there was no further resolution of the LOH size or mutational testi… (full text at CIViC) PMID 9499454 · Fults et al., 1998 · Open in CIViC | civic |
| PTEN R233*1 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Does Not Support Poor Outcome | 3 | accepted | EID343PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients. PMID 22479427 · Carico et al., 2012 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| (oncogenic) | Anaplastic AstrocytomaALIAS | Oncogenic | D | Supports Oncogenicity | 3 | accepted | EID11450Authors demonstrated that a flag-tagged QKI::NTRK2 (e6::e16) fusion was able to transform Ink4a−/−/Arf−/− astrocytes, and these cells induced astrocytomas when injected intracranially into mice. QKI… (full text at CIViC) PMID 27402815 · Ni et al., 2017 · Open in CIViC | civic |
| RB1 Loss-of-function1 | ||||||||
| Palbociclib | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID1595A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, Brd… (full text at CIViC) PMID 20354191 · Michaud et al., 2010 · Open in CIViC | civic |
| ROS1 Overexpression1 | ||||||||
| Gefitinib | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 1 | submitted | EID1970Gefitinib resistant clones were subject to RNAseq and the expression of several genes was found to be upregulated. These genes are mainly tyrosine kinase receptors and include ROS1, DDR1 and PDGFRA. T… (full text at CIViC) PMID 25978031 · Aljohani et al., 2015 · Open in CIViC | civic |
| EGFR Fusion2 | ||||||||
| (oncogenic) | GlioblastomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID10934SEC61G::EGFR fusion identified in 4 out of 164 (2.4%) glioblastoma tumors (TCGA GBM working group, patient samples with pathobiology data). Fusion transcripts were confirmed by RNA-seq and were freque… (full text at CIViC) PMID 24120142 · Brennan et al., 2013 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID10935TCGA pan-cancer data analysis of 9,624 tumors across 33 tumor types identified 25,664 fusions. Significantly associated gene fusion and increased expression level (by RNAseq compared to samples withou… (full text at CIViC) PMID 29617662 · Gao et al., 2018 · Open in CIViC | civic |
| SLC12A2 OVEREXPRESSION1 | ||||||||
| Antisecretory Factor-enriched Egg Yolk Powder Supplement + TemozolomideCombination | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12689Antisecretory factor (AF) induction by the SPC diet or Salovum in GBM xenografts (GBM43, GBM6) reduced NKCC1-mediated chloride influx, chloride permeability, and blocked regulatory volume increase in … (full text at CIViC) PMID 29431617 · Ilkhanizadeh et al., 2018 · Open in CIViC | civic |
| SMARCA4 Loss1 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | A | Supports Positive | 5 | submitted | EID8864Atypical teratoid/rhabdoid tumor (AT/RT) is now defined by WHO guidelines by alterations of either INI1 (SMARCB1) or BRG1 (SMARCA4; rarely mutated) which result in loss of tumor nuclear expression of … (full text at CIViC) PMID 27157931 · Louis et al., 2016 · Open in CIViC | civic |
| SMARCB1 Deletion + SMARCB1 Single nucleotide variant1 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | B | Supports Positive | 4 | submitted | EID11177325 ATRTs underwent methylation profiling, revealing three methylation distinct clusters - ATRT-TYR, ATRT-SHH and ATRT-MYC. In the ATRT-TYR subgroup, the characteristic pattern of SMARCB1 loss was of … (full text at CIViC) PMID 31889194 · Ho et al., 2020 · Open in CIViC | civic |
| SMARCB1 Loss3 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | A | Supports Positive | 5 | submitted | EID8863Atypical teratoid/rhabdoid tumor (AT/RT) is now defined by WHO guidelines by alterations of either INI1 (SMARCB1) or BRG1 (SMARCA4; rarely mutated) which result in loss of tumor nuclear expression of … (full text at CIViC) PMID 27157931 · Louis et al., 2016 · Open in CIViC | civic |
| 〃 | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | B | Supports Positive | 4 | accepted | EID886253 pediatric tumors consisting of 20 AT/RT, 10 PNET, and 23 other central nervous system tumors were classified using microscopic diagnosis, and then tested for expression of the SMARCB1 gene product … (full text at CIViC) PMID 15105654 · Judkins et al., 2004 · Open in CIViC | civic |
| Tazemetostat | Atypical Teratoid/Rhabdoid Tumor | Predictive | B | Supports Sensitivity Response | ||||
| SMARCB1 LOSS OF NUCLEAR PROTEIN EXPRESSION3 | ||||||||
| (diagnostic) | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 4 | accepted | EID12332This study compared cribriform neuroepithelial tumor (CRINET) and atypical teratoid/rhabdoid tumor (AT/RT) to determine whether CRINET is a distinct entity or a variant of AT/RT. The study contained 1… (full text at CIViC) PMID 27380723 · Johann et al., 2017 · Open in CIViC | civic |
| 〃 | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 3 | accepted | EID12327This is the first case report of cribriform neuroepithelial tumor (CRINET), a rare brain cancer identified in a 26-month-old girl and a 10-month-old boy, affecting the third and fourth ventricles. His… (full text at CIViC) PMID 19915490 · Hasselblatt et al., 2009 · Open in CIViC | civic |
| 〃 | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports | ||||
| SMO D473H3 | ||||||||
| Patidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1099Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation. PMID 22550175 · Lee et al., 2012 · Open in CIViC | civic |
| Vismodegib | MedulloblastomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID745In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib). PMID 19726788 · Yauch et al., 2009 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Predictive | D | |||||
| SNCAIP Tandem duplication1 | ||||||||
| (diagnostic) | Medulloblastoma, Non-WNT/Non-SHH, Group 4 | Diagnostic | B | Supports Positive | 3 | submitted | EID11193Analysis of somatic copy number alterations (SCNAs) in 1087 medulloblastoma tumours identified a recurrent tandem duplication of SNCAIP that was restricted to Group 4 medulloblastoma. SNCAIP duplicati… (full text at CIViC) PMID 22832581 · Northcott et al., 2012 · Open in CIViC | civic |
| SUFU Deletion1 | ||||||||
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID5324In a sonic hedgehog driven medulloblastoma patient derived xenograft harbouring a SUFU deletion, SMO inhibition with LDE225 (Sonidegib) did not affect cell proliferation. PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| TERT C228T2 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID6934Evaluation of 25 Korean patients with primary glioblastomas, individuals with TERT promoter mutations (N=16) had worse overall survival (median 81.7 weeks [95% confidence interval (CI), 61.71–101.85])… (full text at CIViC) PMID 29344264 · Jeong et al., 2017 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Prognostic | D | Supports Poor Outcome | 2 | submitted | EID6935Surgical samples from 25 Korean patients with primary glioblastomas were disassociated for cell culture and evaluated for TERT promoter mutations (N=16 mutant, N=9 wildtype). All patients harbored the… (full text at CIViC) PMID 29344264 · Jeong et al., 2017 · Open in CIViC | civic |
| TERT C250T1 | ||||||||
| (oncogenic) | GlioblastomaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID10331TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspo… (full text at CIViC) PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC | civic |
| TERT Promoter Mutation2 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID516In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27%… (full text at CIViC) PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID6933In 50 patients with primary glioblastomas, patients without TERT promoter mutations (N=13, median 27 mo) survived longer than those harboring mutations (N=37, 14 mo; P = 0.01 by the log rank test; HR … (full text at CIViC) PMID 23530248 · Killela et al., 2013 · Open in CIViC | civic |
| TP53 M237I2 | ||||||||
| Unspecified therapy | GlioblastomaCURATED_BROADER | Predictive | C | Supports N/A | 5 | submitted | EID8064mutants in diverse tumor types activate different p53 target genes, but some may give rise to the same GoF phenotype. 12,13 For example, M237I, in glioblastoma, and R282W, in lung cancer, trigger chem… (full text at CIViC) PMID 29260852 · Silva et al., 2018 · Open in CIViC | civic |
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID7979The glioblastoma T98G cell line possesses a TP53 M237I variant. This cell line initially exhibited resistance to temozolomide treatment, but a five-fold increase in chemosensitivity (IC50 112.15 ug/ml… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| TP53 Mutation8 | ||||||||
| (predisposing) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predisposing | B | Supports Predisposition | 5 | submitted | EID8346This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC | civic |
| (prognostic) | Medulloblastoma, SHH-Activated | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID8347In the childhood (≥4.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3… (full text at CIViC) PMID 28545823 · Schwalbe et al., 2017 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | ||||||
| TP53 R273H1 | ||||||||
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID7980The glioblastoma U138 cell line possesses a TP53 R273H variant. This cell line initially exhibited resistance to temozolomide treatment, but a four-fold increase in chemosensitivity (IC50 127.79 ug/ml… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Gliosarcoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID11746A 9-month-old boy with no family history of cancer presented with increased head circumference, and MRI demonstrated a solid lesion in the left frontal lobe. A subtotal surgical resection was performe… (full text at CIViC) PMID 35034013 · Mançano et al., 2022 · Open in CIViC | civic |
| VEGFA Overexpression1 | ||||||||
| Bevacizumab | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7013We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2). PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC | civic |
| VEGFA Overexpression of VEGF1211 | ||||||||
| Bevacizumab | GlioblastomaCURATED_BROADER | Predictive | B | Supports Resistance | 4 | submitted | EID9490In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression. PMID 29747600 · Martini et al., 2018 · Open in CIViC | civic |
| WDR12 OVEREXPRESSION1 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8004Expression of WDR12 was found to be significantly higher in tumour than normal tissue from TCGA LGG and GBM datasets. Kaplan-Meier analysis showed high WDR12 expression to be significantly associated … (full text at CIViC) PMID 32180229 · Li et al., 2020 · Open in CIViC | civic |
| WEE1 Overexpression2 | ||||||||
| Adavosertib | Diffuse Midline Glioma, H3 K27-Altered | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7242Significant WEE1 protein overexpression was detected by IHC in VUMC-DIPG-1 tissue isolated from a patient's frontal lobe. Significant WEE1 protein levels were also found in E98-FM glioma cells. An i… (full text at CIViC) PMID 23270927 · Caretti et al., 2013 · Open in CIViC | civic |
| 〃 | Diffuse Midline Glioma, H3 K27-Altered | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7243Two mouse xenograft models were used: one of tumor cells from a genetically engineered mouse with a BRAF V600E mutation, and the other using a patient's DIPG cells (SF8628). SF8628 was found to have … (full text at CIViC) PMID 24305702 · Mueller et al., 2014 · Open in CIViC | civic |
| MAML2 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma ZFTA Fusion-Positive | Diagnostic | C | Supports Positive | 2 | accepted | EID11430In an analysis of 13 cases of supratentorial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependymoma. … (full text at CIViC) PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC | civic |
| NCOA1 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma ZFTA Fusion-Positive | Diagnostic | C | Supports Positive | 2 | accepted | EID11428In an analysis of 13 cases of supratentorial glial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependy… (full text at CIViC) PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC | civic |
Data updated 14 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| B |
| Supports Resistance |
| 4 |
| submitted |
EID8176In this retrospective study of 66 GBM patients treated with PD-1 inhibitors (nivolumab or pembrolizumab) at recurrence, mutations in PTEN were frequently found among non-responders. Of 45 IDH1 wild-ty… (full text at CIViC) PMID 30742119 · Zhao et al., 2019 · Open in CIViC |
| civic |
| 3 |
| submitted |
EID11180In the dose expansion of phase I pediatric trial (NCT02601937) of the EZH2 inhibitor tazemetostat, the overall response in 21 patients with SMARCB1-deficient atypical teratoid rhabdoid tumors (ATRT) w… (full text at CIViC) |
| civic |
| 3 |
| accepted |
EID12328This study explored the molecular features of cribriform neuroepithelial tumors (CRINET) using multiplex ligation-dependent probe amplification (MLPA) and molecular inversion profiling (MIP) assays al… (full text at CIViC) PMID 26352987 · Gessi et al., 2015 · Open in CIViC |
| civic |
| — |
| submitted |
EID4427In an in vitro study, a C3H10T1/2 cell line expressing SMO D473H mutation, demonstrated resistance to vismodegib treatment (IC50: 3,000,000 nmol/L vs. 20 nmol/L) compared to C3H10T1/2 cells expressing… (full text at CIViC) PMID 21123452 · Dijkgraaf et al., 2011 · Open in CIViC |
| civic |
| B |
| Supports Poor Outcome |
| 4 |
| submitted |
EID7963This study showed that patients with TP53 mutated medulloblastoma (8/49, 16%) exhibited worse prognosis compared to those with wildtype medulloblastoma (41/49, 84%). A 5-year overall survival of 0% wa… (full text at CIViC) PMID 20142599 · Tabori et al., 2010 · Open in CIViC |
| civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID7964This study examined the prognostic implication of TP53 mutation status in different molecular subgroups of medulloblastoma. A discovery cohort of 397 patients and a validation cohort of 156 cases were… (full text at CIViC) PMID 23835706 · Zhukova et al., 2013 · Open in CIViC | civic |
| (diagnostic) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID8345One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID7976In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Patients with TP53 mutation were found t… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | B | Supports Resistance | 3 | submitted | EID7978In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Kaplan-Meier analysis of the 35 patients… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| Vismodegib | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID8348Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC | civic |